The prognostic significance of B lymphocytes in invasive carcinoma of the breast

Breast Cancer Research and Treatment

Volumn 132, Issue 2, 2012, Pages 545-553

  Mahmoud, S M A ^a,b   Lee, A H S ^c   Paish, E C ^c   MacMillan, R D ^c   Ellis, I O ^a,c   Green, A R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MANSOURA UNIVERSITY   (Egypt)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

B lymphocytes; Breast cancer; CD20; Humoral immunity; Immunohistochemistry

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; B LYMPHOCYTE; BREAST CARCINOMA; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL AGGREGATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; ANTIGENS, CD20; B-LYMPHOCYTES; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; ENGLAND; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859102962     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1620-1     Document Type: Article

References (52)

1. Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC et al (2007) Therapeutic Bcell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 104(52):20878-20883
2. Crawford A, Macleod M, Schumacher T, Corlett L, Gray D (2006) Primary Tcell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 176(6): 3498-3506 (Pubitemid 43363997)
3. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH (2004) RNA-transfected CD40-activated Bcells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103(6):2046-2054 (Pubitemid 38326219)
4. Schultz KR, Klarnet JP, Gieni RS, HayGlass KT, Greenberg PD (1990) The role of Bcells for in vivo T cell responses to a Friend virus-induced leukemia. Science 249(4971):921-923
5. de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7(5):411-423 (Pubitemid 40719125)
6. Houghton AN, Uchi H, Wolchok JD (2005) The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell 7(5):403-405 (Pubitemid 40719122)
7. Bernatsky S, Ramsey-Goldman R, Clarke A (2006) Malignancy and autoimmunity. Curr Opin Rheumatol 18(2):129-134 (Pubitemid 43740384)
8. Tomer Y, Sherer Y, Shoenfeld Y (1998) Autoantibodies, autoimmunity and cancer (review). Oncol Rep 5(3):753-761
9. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB et al (2009) Systematic analysis of immune infiltrates in highgrade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4(7):e6412
10. Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG et al (2006) NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 125(3):451-458 (Pubitemid 43327717)
11. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14(16):5220-5227
12. Kuroda H, Tamaru J, Sakamoto G, Ohnisi K, Itoyama S (2005) Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast. Virchows Arch 446(1):10-14 (Pubitemid 40179150)
13. Hansen MH, Nielsen HV, Ditzel HJ (2002) Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells. J Immunol 169(5): 2701-2711 (Pubitemid 34921019)
14. Hansen MH, Nielsen H, Ditzel HJ (2001) The tumor-infiltrating Bcell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 98(22):12659-12664 (Pubitemid 33020002)
15. Lee AH, Happerfield LC, Bobrow LG, Millis RR (1997) Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 50(8):669-673 (Pubitemid 27396070)
16. Nzula S, Going JJ, Stott DI (2003) Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 63(12):3275-3280 (Pubitemid 36735883)
17. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H et al (2002) Antigen-driven oligoclonal expansion of tumorinfiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169(4):1829-1836 (Pubitemid 34857644)
18. Lee AH, Happerfield LC, Millis RR, Bobrow LG (1996) Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast. Br J Cancer 74(5):796-801 (Pubitemid 26300773)
19. Tedder TF, Engel P (1994) CD20: aregulator of cell-cycle progression of B lymphocytes. Immunol Today 15(9):450-454 (Pubitemid 24272191)
20. Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of ahuman B lymphocyte-specific antigen. J Immunol 125(4):1678-1685
21. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8:140-174
22. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large wellcharacterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340-350 (Pubitemid 40993329)
23. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495-506 (Pubitemid 43329336)
24. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
25. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW (1992) Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20(6):479-489
26. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22(3):207-219
27. Pinder SE, Ellis IO, Galea M, O'Rouke S, Blamey RW, Elston CW (1994) Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24(1): 41-47
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067-9072
29. Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80(12): 1943-1949 (Pubitemid 32012762)
30. + infiltrating cells in human breast cancer. Breast Cancer Res Treat 127(1):99-108
31. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 39(6):857-865
32. + lymphocytes predicts clinical outcome in breast cancer. J Clin Oncol 29(15): 1949-1955
33. Cox DR (1972) Regression models and life-tables. J R Stat Soc Series B Stat Methodol 34(2):187-220
34. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: anew bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10(21):7252-7259 (Pubitemid 39487712)
35. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL (2006) Quantitative insitu analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66(10):5487-5494 (Pubitemid 43844977)
36. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF et al (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661-671 (Pubitemid 38714103)
37. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers intriple-negative breast cancer. Cancer 109(1):25-32 (Pubitemid 46120191)
38. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF et al (2006) Basal phenotype identifies apoor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149-3156 (Pubitemid 44854512)
39. Marsigliante S, Biscozzo L, Marra A, Nicolardi G, Leo G, Lobreglio GB et al (1999) Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. Cancer Lett 139(1):33-41 (Pubitemid 29222021)
40. Naukkarinen A, Syrjanen KJ (1990) Quantitative immunohistochemical analysis of mononuclear infiltrates in breast carcinomas-correlation with tumour differentiation. J Pathol 160(3): 217-222 (Pubitemid 20115503)
41. Stewart TH, Heppner GH (1997) Immunological enhancement of breast cancer. Parasitology 115(Suppl):S141-S153
42. Rohrer JW, Barsoum AL, Dyess DL, Tucker JA, Coggin JH Jr (1999) Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. J Immunol 162(11):6880-6892 (Pubitemid 29309417)
43. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL et al (2006) Quantification of regulatory Tcells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373-5380 (Pubitemid 46623168)
44. Bilik R, Mor C, Hazaz B, Moroz C (1989) Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol Immunother 28(2):143-147 (Pubitemid 19039769)
45. Georgiannos SN, Renaut A, Goode AW, Sheaff M (2003) The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. Surgery 134(5):827-834 (Pubitemid 37523968)
46. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E et al (1992) Lymphocyte infiltrates as aprognostic variable in female breast cancer. Eur J Cancer 28A(4-5):859-864
47. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H et al (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68(13):5405-5413
48. Lee AH, Gillett CE, Ryder K, Fentiman IS, Miles DW, Millis RR (2006) Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology 48(6):692-701
49. Lee AHS (2008) Inflammation and vascularity in carcinoma of the breast. University of Cambridge, Cambridge
50. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A et al (1990) Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125(2):200-205 (Pubitemid 20060644)
51. Lee YT, Sheikh KM, Quismorio FP Jr, Friou GJ (1985) Circulating anti-tumor and autoantibodies in breast carcinoma: relationship to stage and prognosis. Breast Cancer Res Treat 6(1):57-65 (Pubitemid 15241230)
52. Coronella-Wood JA, Hersh EM (2003) Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother 52(12):715-738 (Pubitemid 37491701)